Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 3/20 | 0.55 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | PRKCI | P41743 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.33 |
| ▸ | PARP11 | Q9NR21 | 2/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | AKT1S1 | Q96B36 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13996732 | 0.78 | NNMT (0.55) | NNMTNOTUMPARP10PARP11GRM5 | |
| SCHEMBL13343936 | 0.75 | NNMT (0.73) | NNMTNOTUM | |
| SCHEMBL12904664 | 0.72 | NNMT (0.68) | NNMTPARP1 | |
| SCHEMBL23188818 | 0.72 | NNMT (0.37) | NNMT | |
| SCHEMBL16196568 | 0.71 | NNMT (0.45) | NNMTUHRF1AKT1S1 | |
| SCHEMBL7214252 | 0.71 | NNMT (0.53) | NNMTUHRF1DRD1PARP10PARP11 | |
| SCHEMBL25787745 | 0.71 | NNMT (1.00) | NNMTNOTUM | |
| SCHEMBL795352 | 0.71 | NNMT (0.44) | NNMTUHRF1DRD1PARP10PARP11 | |
| SCHEMBL7213850 | 0.70 | NNMT (0.55) | NNMTUHRF1DRD1PARP10PARP11 | |
| SCHEMBL25795779 | 0.70 | NNMT (0.55) | NNMTUHRF1DRD1PARP10PARP11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111547-A1 | 2,3-DIHYDROPYROLLOPYRIDINE CARBOXAMIDE COMPOUNDS AND METHODS OF USE THEREOF | RGENTA THERAPEUTICS, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| US-20110152258-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON INC. | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152258-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | BRAF, KRAS, RAF1 | NNMT 3056/4885UHRF1 2767/4885AXL 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.